Literature DB >> 16685082

Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat.

Chunyu Zheng1, Katsunori Ikewaki, Brian W Walsh, Frank M Sacks.   

Abstract

We aimed to identify mechanisms by which apolipoprotein B-48 (apoB-48) could have an atherogenic role by simultaneously studying the metabolism of postprandial apoB-48 and apoB-100 lipoproteins. The kinetics of apoB-48 and apoB-100, each in four density subfractions of VLDL and intermediate density lipoprotein (IDL), were studied by stable isotope labeling in a constantly fed state with half-hourly administration of almond oil in five postmenopausal women. A non-steady-state, multicompartmental model was used. Despite a much lower production rate, VLDL and IDL apoB-48 shared a similar secretion pattern with apoB-100: both were directly secreted into all fractions with similar percentage mass distributions. Fractional catabolic rates (FCRs) of apoB-48 and apoB-100 were similar in VLDL and IDL. We identified a fast turnover compartment of light VLDL that had a residence time of <30 min for apoB-48 and apoB-100. Finally, a high secretion rate of apoB-48 was associated with a slow FCR of VLDL and IDL apoB-100. In conclusion, the intestine secretes a spectrum of apoB lipoproteins, similar to what the liver secretes, albeit with a much lower secretion rate. Once in plasma, intestinal and hepatic triglyceride-rich lipoproteins have similar rates of clearance and participate interactively in similar metabolic pathways, with high apoB-48 production inhibiting the clearance of apoB-100.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16685082      PMCID: PMC3219222          DOI: 10.1194/jlr.M500528-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  39 in total

1.  Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes.

Authors:  F K Welty; A H Lichtenstein; P H Barrett; G G Dolnikowski; E J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-12       Impact factor: 8.311

2.  Models to interpret kinetic data in stable isotope tracer studies.

Authors:  C Cobelli; G Toffolo; D M Bier; R Nosadini
Journal:  Am J Physiol       Date:  1987-11

3.  Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man.

Authors:  J D Brunzell; W R Hazzard; D Porte; E L Bierman
Journal:  J Clin Invest       Date:  1973-07       Impact factor: 14.808

4.  Human chylomicron apolipoprotein metabolism.

Authors:  E J Schaefer; L L Jenkins; H B Brewer
Journal:  Biochem Biophys Res Commun       Date:  1978-01-30       Impact factor: 3.575

5.  Lipoprotein binding to cultured human hepatoma cells.

Authors:  F Krempler; G M Kostner; W Friedl; B Paulweber; H Bauer; F Sandhofer
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

6.  Atherogenesis: a postprandial phenomenon.

Authors:  D B Zilversmit
Journal:  Circulation       Date:  1979-09       Impact factor: 29.690

7.  Kinetic model for production and metabolism of very low density lipoprotein triglycerides. Evidence for a slow production pathway and results for normolipidemic subjects.

Authors:  L A Zech; S M Grundy; D Steinberg; M Berman
Journal:  J Clin Invest       Date:  1979-06       Impact factor: 14.808

8.  Measurement of human apolipoprotein B-48 and B-100 kinetics in triglyceride-rich lipoproteins using [5,5,5-2H3]leucine.

Authors:  A H Lichtenstein; D L Hachey; J S Millar; J L Jenner; L Booth; J Ordovas; E J Schaefer
Journal:  J Lipid Res       Date:  1992-06       Impact factor: 5.922

9.  Chylomicron clearance in normal and hyperlipidemic man.

Authors:  S M Grundy; H Y Mok
Journal:  Metabolism       Date:  1976-11       Impact factor: 8.694

10.  Kinetics of chylomicron remnant clearance in normal and in hyperlipoproteinemic subjects.

Authors:  J A Cortner; P M Coates; N A Le; D R Cryer; M C Ragni; A Faulkner; T Langer
Journal:  J Lipid Res       Date:  1987-02       Impact factor: 5.922

View more
  9 in total

Review 1.  Postprandial Metabolism of Macronutrients and Cardiometabolic Risk: Recent Developments, Emerging Concepts, and Future Directions.

Authors:  Miriam Jacome-Sosa; Elizabeth J Parks; Richard S Bruno; Esra Tasali; Gary F Lewis; Barbara O Schneeman; Tia M Rains
Journal:  Adv Nutr       Date:  2016-03-15       Impact factor: 8.701

Review 2.  Getting the label in: practical research strategies for tracing dietary fat.

Authors:  J E Lambert; E J Parks
Journal:  Int J Obes Suppl       Date:  2012-12-11

3.  Metabolism of apolipoprotein A-II containing triglyceride rich ApoB lipoproteins in humans.

Authors:  Nirav K Desai; Esther M Ooi; Paul D Mitchell; Jeremy Furtado; Frank M Sacks
Journal:  Atherosclerosis       Date:  2015-05-19       Impact factor: 5.162

4.  Multiple apolipoprotein kinetics measured in human HDL by high-resolution/accurate mass parallel reaction monitoring.

Authors:  Sasha A Singh; Allison B Andraski; Brett Pieper; Wilson Goh; Carlos O Mendivil; Frank M Sacks; Masanori Aikawa
Journal:  J Lipid Res       Date:  2016-02-09       Impact factor: 5.922

5.  Dietary monounsaturated fat activates metabolic pathways for triglyceride-rich lipoproteins that involve apolipoproteins E and C-III.

Authors:  Chunyu Zheng; Christina Khoo; Jeremy Furtado; Katsunori Ikewaki; Frank M Sacks
Journal:  Am J Clin Nutr       Date:  2008-08       Impact factor: 7.045

6.  Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.

Authors:  Julio Alejandro Lamprea-Montealegre; Natalie Staplin; William G Herrington; Richard Haynes; Jonathan Emberson; Colin Baigent; Ian H de Boer
Journal:  Clin J Am Soc Nephrol       Date:  2019-12-12       Impact factor: 8.237

Review 7.  Causes and Consequences of Hypertriglyceridemia.

Authors:  Chris J Packard; Jan Boren; Marja-Riitta Taskinen
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-14       Impact factor: 5.555

8.  ApoC-III and visceral adipose tissue contribute to paradoxically normal triglyceride levels in insulin-resistant African-American women.

Authors:  Anne E Sumner; Jeremy D Furtado; Amber B Courville; Madia Ricks; Novie Younger-Coleman; Marshall K Tulloch-Reid; Frank M Sacks
Journal:  Nutr Metab (Lond)       Date:  2013-12-23       Impact factor: 4.169

9.  Pediatric Metabolic Syndrome: Pathophysiology and Laboratory Assessment.

Authors:  Victoria Higgins; Khosrow Adeli
Journal:  EJIFCC       Date:  2017-03-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.